Bicycle Therapeutics PLC
BCYC7.990USD
0.000
交易中 （美東）報價延遲15分鐘
552.93M總市值
虧損本益比TTM
關於 Bicycle Therapeutics PLC 公司
Bicycle Therapeutics plc 是一家位於英國的臨牀階段生物製藥公司，正在開發一種新型藥物，稱爲 Bicycle 分子，用於治療現有療法無法治療的疾病。Bicycle 分子是完全合成的短肽，被小分子支架束縛，形成兩個環，以穩定其結構幾何形狀。該公司正在公司贊助的臨牀試驗中評估 BT8009，一種針對經過充分驗證的腫瘤抗原 Nectin-4 的 Bicycle 毒素結合物 (BTC)；BT5528，一種針對歷史上無法用藥的靶點 EphA2 的 BTC；以及 BT7480，一種針對 Nectin-4 和激動 CD137 的 Bicycle 腫瘤靶向免疫細胞激動劑 (Bicycle TICA)。此外，該公司正在開發用於放射性藥物的 Bicycle 放射性結合物 (BRC)，並通過各種合作伙伴關係，探索利用 Bicycle 技術開發腫瘤以外疾病的治療方法。其候選產品還包括 BT1718 和 BT7455。
公司簡介
公司代碼BCYC
公司名稱Bicycle Therapeutics PLC
上市日期May 23, 2019
CEODr. Kevin Lee, Ph.D.
員工數量305
證券類型Depository Receipt
年結日May 23
公司地址Blocks A & B, Portway Building
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United Kingdom
郵編CB21 6GS
電話11441223261503
網址https://www.bicycletherapeutics.com/
公司代碼BCYC
上市日期May 23, 2019
CEODr. Kevin Lee, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
275.59K
-23.43%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
72.92K
+73.03%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
25.33K
-65.69%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
18.31K
+49.49%
Mr. Eric Westin, M.D.
Mr. Eric Westin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stephen Sands
Mr. Stephen Sands
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Felix J. Baker, Ph.D.
Mr. Felix J. Baker, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Michael Hannay
Mr. Michael Hannay
Chief Product and Supply Chain Officer
Chief Product and Supply Chain Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
275.59K
-23.43%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
72.92K
+73.03%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
25.33K
-65.69%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
18.31K
+49.49%
Mr. Eric Westin, M.D.
Mr. Eric Westin, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月14日 週一
更新時間: 7月14日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Baker Bros. Advisors LP
22.79%
Point72 Asset Management, L.P.
7.73%
Forbion Capital Partners
7.23%
Armistice Capital LLC
5.59%
Westfield Capital Management Company, L.P.
5.56%
Other
51.09%
持股股東
持股股東
佔比
Baker Bros. Advisors LP
22.79%
Point72 Asset Management, L.P.
7.73%
Forbion Capital Partners
7.23%
Armistice Capital LLC
5.59%
Westfield Capital Management Company, L.P.
5.56%
Other
51.09%
股東類型
持股股東
佔比
Hedge Fund
47.52%
Investment Advisor
17.21%
Investment Advisor/Hedge Fund
15.44%
Venture Capital
9.66%
Research Firm
3.69%
Individual Investor
1.60%
Pension Fund
0.20%
Family Office
0.06%
Other
4.61%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
261
45.57M
95.34%
-15.98M
2025Q1
263
46.04M
96.46%
-15.64M
2024Q4
263
44.84M
86.26%
-16.34M
2024Q3
260
44.49M
67.19%
-14.65M
2024Q2
252
44.12M
95.17%
-7.15M
2024Q1
268
34.84M
83.52%
-13.88M
2023Q4
272
34.95M
93.64%
-12.28M
2023Q3
272
41.70M
105.20%
-747.70K
2023Q2
255
34.13M
112.16%
-8.01M
2023Q1
245
32.53M
108.64%
-4.04M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Baker Bros. Advisors LP
10.89M
22.79%
-8.80K
-0.08%
Mar 31, 2025
Point72 Asset Management, L.P.
3.69M
7.73%
-862.83K
-18.94%
Mar 31, 2025
Forbion Capital Partners
3.45M
7.23%
--
--
Mar 31, 2025
Armistice Capital LLC
2.67M
5.59%
+476.00K
+21.68%
Mar 31, 2025
Westfield Capital Management Company, L.P.
2.66M
5.56%
+46.97K
+1.80%
Mar 31, 2025
Invus Public Equities Advisors, LLC
1.81M
3.8%
-26.65K
-1.45%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.54M
3.22%
-48.54K
-3.06%
Mar 31, 2025
Candriam Luxembourg S.A.
1.21M
2.53%
-20.80K
-1.69%
May 31, 2025
Long Focus Capital Management LLC
1.29M
2.71%
+750.66K
+138.22%
Mar 31, 2025
BNP Paribas Asset Management USA, Inc.
1.22M
2.55%
+64.04K
+5.54%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.72%
Harbor Health Care ETF
0.68%
Invesco NASDAQ Future Gen 200 ETF
0.38%
ALPS Medical Breakthroughs ETF
0.22%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Health Innovation Active ETF
0.03%
iShares Biotechnology ETF
0.02%
SPDR S&P International Small Cap ETF
0.02%
Tema Oncology ETF
0%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.72%
Harbor Health Care ETF
佔比0.68%
Invesco NASDAQ Future Gen 200 ETF
佔比0.38%
ALPS Medical Breakthroughs ETF
佔比0.22%
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
iShares Health Innovation Active ETF
佔比0.03%
iShares Biotechnology ETF
佔比0.02%
SPDR S&P International Small Cap ETF
佔比0.02%
Tema Oncology ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
